Publikationen in Zusammenarbeit mit Forschern von Universidad Complutense de Madrid (28)

2024

  1. Astrocytic GLUT1 reduction paradoxically improves central and peripheral glucose homeostasis

    Science Advances , Vol. 10, Núm. 42

  2. Emotional intelligence and neurocognition profiles in first-episode psychosis: A two-year follow-up study

    European Neuropsychopharmacology, Vol. 85, pp. 66-77

  3. Exploring the reactivity of bicyclic α-iminophosphonates to access new imidazoline I2 receptor ligands

    Bioorganic Chemistry, Vol. 142

  4. Negative symptoms and sex differences in first episode schizophrenia: What's their role in the functional outcome? A longitudinal study

    Spanish Journal of Psychiatry and Mental Health

  5. The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls

    EMBO Molecular Medicine, Vol. 16, Núm. 4, pp. 755-783

2023

  1. Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer’s Disease

    Pharmaceutics, Vol. 15, Núm. 10

  2. Selective inhibition of cannabinoid CB1 receptor-evoked signalling by the interacting protein GAP43

    Neuropharmacology, Vol. 240

2022

  1. NRN1 Gene as a Potential Marker of Early-Onset Schizophrenia: Evidence from Genetic and Neuroimaging Approaches

    International Journal of Molecular Sciences, Vol. 23, Núm. 13

  2. Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines

    European Journal of Internal Medicine, Vol. 99, pp. 19-21

2021

  1. Identification of bip as a cb1 receptor-interacting protein that fine-tunes cannabinoid signaling in the mouse brain

    Journal of Neuroscience, Vol. 41, Núm. 38, pp. 7924-7941

  2. Paliperidone Reversion of Maternal Immune Activation-Induced Changes on Brain Serotonin and Kynurenine Pathways

    Frontiers in Pharmacology, Vol. 12

2020

  1. Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study

    Schizophrenia Research, Vol. 218, pp. 292-294

2019

  1. Therapeutic targeting of HER2–CB 2 R heteromers in HER2-positive breast cancer

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 9, pp. 3863-3872

  2. Erratum: Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (3863–3872) DOI: 10.1073/pnas.1815034116)

    Proceedings of the National Academy of Sciences of the United States of America

  3. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 2, pp. 92-105

2018

  1. Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: Effect of antidepressants

    Journal of Neuroinflammation, Vol. 15, Núm. 1

2017

  1. Paliperidone reverts Toll-like receptor 3 signaling pathway activation and cognitive deficits in a maternal immune activation mouse model of schizophrenia

    Neuropharmacology, Vol. 116, pp. 196-207

2016

  1. Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer

    Oncotarget, Vol. 7, Núm. 30, pp. 47565-47575

2015

  1. Altered CB1 receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects

    Journal of Psychopharmacology, Vol. 29, Núm. 11, pp. 1137-1145

  2. The endocannabinoid system is altered in the post-mortem prefrontal cortex of alcoholic subjects

    Addiction Biology, Vol. 20, Núm. 4, pp. 773-783